AC Immune SA

AC Immune SA

AC Immune SA

Overview
Date Founded

2003

Headquarters

EPFL Innovation Park, Building B, Lausanne, 1015, CHE

Type of Company

Public

Employees (Worldwide)

104

Industries

Pharmaceuticals
Biotechnology

Company Description

AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Contact Data
Trying to get in touch with decision makers at AC Immune SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer

Chief Scientific Officer

Chief Scientific Officer, Deputy & Head of Non-Ad Proteinopathies

Head of Technical Operations & Program Management

Head of Translational Science

Head of the Clinical Team

Chief Administrative Officer

Clinical Advisor

Secretary

Board of Directors

Founding President & Chief Executive Officer at Codiak Biosciences, Inc.

Co-Founder, Director at Sumerian Europe Ltd.

Co-Founder at AC Immune SA

Chief Executive Officer at Evotec SE

Co-Founder & Managing Director at dievini Hopp BioTech holding GmbH & Co. KG

Chief Financial Officer at Generation Bio Co.

Professional at AC Immune SA

Director at AC Immune SA

Paths to AC Immune SA
Potential Connections via
Relationship Science
You
AC Immune SA
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Founded in 2008, Prosight Management LP is a hedge fund manager located in Dallas, Texas. The firm also does business as Prosight Capital. They manage the Prosight Fund LP.

Details Hidden

Founded in 2008, Prosight Management LP is a hedge fund manager located in Dallas, Texas. The firm also does business as Prosight Capital. They manage the Prosight Fund LP.

Recent Transactions
Details Hidden

AC Immune SA issued Common Stock

Details Hidden

AC Immune SA issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onAC Immune SA issued Common Stock

Auditor

Advised onAC Immune SA issued Common Stock

Underwriter

Advised onAC Immune SA issued Common Stock

Counsel

Advised onAC Immune SA issued Common Stock

Legal Advisor

Advised onAC Immune SA issued Common Stock

Associate

Advised onAC Immune SA issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Key Stats and Financials As of 2018
Market Capitalization
$339M
Total Enterprise Value
$396M
Earnings Per Share
$-0.84
Revenue
$7.35M
Net Profit
$-52.1M
EBITDA
$-49.6M
EBITDAMargin
-675.41%
Total Debt
$526K
Total Equity
$180M
Enterprise Value Sales
53.84x
TEVNet Income
-7.6x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-43.12%
Investors
Details Hidden

Co-Founder at AC Immune SA

Details Hidden

Co-Founder, Director at Sumerian Europe Ltd.

Details Hidden

Co-Managing Director at Dietmar Hopp Stiftung GmbH

Suppliers
Bachem Holding AG Wholesale: Consumer Non-Durables/Sundries | Bubendorf, BL

Bachem Holding AG is a technology-based biochemical company, which engages in the provision of services to the pharmaceutical and biotechnology industries. The company operates through the Europe and North America geographical segments. It specializes in the development of manufacturing processes and the production of peptide-based active pharmaceutical ingredients. The company was founded in 2003 and is headquartered in Bubendorf, Switzerland.

Evonik Industries AG Industrial Machinery & Manufacturing | Essen, NW

Evonik Industries AG is a holding company, which engages in the manufacture of specialty chemical products. It operates through the following segments: Nutrition and Care, Resource Efficiency, Performance Materials, and Services. The Nutrition and Care segment includes specialty chemicals for consumer goods for daily needs, animal nutrition, and healthcare products. The Resource Efficiency segment supplies materials and specialty additives for environment-friendly and energy-efficient system solutions for the automotive, paints, coatings, adhesives, construction industries, and other sectors. The Performance Materials segment produces polymer materials and intermediates, mainly for the rubber, plastics, and agriculture industries. The Services segment comprises site services, process technology, and administrative services. The company was founded in 1919 and is headquartered in Essen, Germany.

Roche Holding AG Medical Support Services | Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Awards & Honors
2009
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AC Immune SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AC Immune SA's profile does not indicate a business or promotional relationship of any kind between RelSci and AC Immune SA.